<DOC>
	<DOCNO>NCT01543048</DOCNO>
	<brief_summary>CIN2/3 increase many year mainly concern woman age 25-29 year . They subsequent persistent HPV infection classically treat conization . Recurrences occur 7 18 % case , mainly CIN3 management first 2 year follow-up . Follow-up crucial detect treat recurrence select high risk woman might develop cervical cancer . Colposcopy cytology recommend since 1989 French ANAES , method poor sensitivity specificity . However , DNA HPV test sensitive demonstrate high negative predictive value , specificity positive predictive value remain average . Other HPV marker like genotyping , viral load integration begin use screening investigated CIN2/3 follow-up ass value various HPV marker predict CIN2/3 recurrence conization . The primary objective describe HPV expression ( genotyping , viral load , mRNA E6 E7 ) time conization follow-up period ( 6 , 12 , 24 month ) assess prognostic value HPV 16 expression ( viral load , mRNA E6 E7 ) determine risk CIN2/3 recurrence conization , compare clinical virological risk factor .</brief_summary>
	<brief_title>Prognostic Value Human Papillomavirus ( HPV ) Detection Cervical Intra-epithelial Neoplasia ( CIN ) Recurrence After Conization</brief_title>
	<detailed_description>Women CIN3 treat conization consecutively include study 12 month . They recruit 3 main University Hospitals South West France ( Bordeaux , Toulouse , Limoges ) followed-up 24 month . Colposcopy ( +/- biopsy ) , cytology , virology test perform time conization follow-up period ( 6 , 12 , 24 month ) . HPV expression assess centralize validated marketed test ( Hybrid Capture 2 , RLA genotyping , PreTectÂ® HPV-Proofer ) real time PCR measuring E2 , E6 E7 viral load HPV 1 .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<criteria>Women 18 year CIN 2 3 diagnosis inclusion confirm CIN3 diagnosis conization . HPV detect Hybrid Capture 2 RLA genotyping . Informed sign consent patient investigator Coverage French social security Pregnancy time inclusion . Previous history conization . Atypical endometrial glandular cell evidence carcinoma conization . Previous vaccination prophylactic HPV vaccine . Active viral infection include HIV . Acquired congenital immunodeficiency . Long term treatment corticosteroid immunosuppressive drug . Persons protection law . Patients unable meet requirement protocol . Any condition , accord investigator , would prevent participation study interfere objective study ( refusal supervision University Hospital , expect change address within 3 year , etc )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Human Papilloma Virus ( HPV )</keyword>
	<keyword>Virological test</keyword>
	<keyword>CIN3</keyword>
	<keyword>Cervical cancer</keyword>
	<keyword>Conization</keyword>
	<keyword>within woman treat conization CIN3</keyword>
</DOC>